SANSUM DIABETES
RESEARCH INSTITUTE

2024 IMPACT REPORT

MESSAGE FROM BOARD PRESIDENT & CEO

CONTENTS

2 Board President & CEO Message

3 100+ Years of Landmark Discoveries

4 2024 Clinical Trials

5 2024 Published Articles

6 Future Goals

8 SDRI Program Highlights

9 Financials

10 2024 Donors

Dear Friends,

Thanks to your support, 2024 was a year of remarkable progress at Sansum Diabetes Research Institute (SDRI). At the heart of our mission, clinical research trials, our work delivered real solutions for people living with diabetes. From pioneering studies in automated insulin delivery systems to advancing new approaches for women with diabetes during pregnancy, SDRI research once again demonstrated how science translates into better treatments, earlier diagnoses, and more hopeful futures.

Our findings were published in leading medical journals and presented on the global stage at scientific meetings across the United States and Europe. SDRI's voice is guiding the international conversation on the future of diabetes care.

Looking ahead, we are building on this momentum. Renovations are underway to complete our building remodel in the first quarter of 2026, a space designed to accelerate discoveries that will change the trajectory of diabetes care. This investment ensures SDRI will remain at the forefront of diabetes research, translating ideas into impact for millions worldwide.

We recognize that the challenges are great. Diabetes continues to rise, with a profound impact on women, children, and underserved communities. Yet, with your partnership, SDRI is poised to meet these challenges with determination, compassion, and scientific rigor.

The story of SDRI is one of resilience, innovation, and hope. Together – with our dedicated team, generous supporters, and global collaborators – we are building a future where better treatments, earlier interventions, and ultimately prevention are within reach.

We extend our deepest gratitude to every donor, participant, and partner who made 2024 extraordinary. The progress of this past year is only the beginning, and with your continued support, the most exciting breakthroughs are still ahead.

Yours in purpose and progress,

Jim Sloan
President, Board of Trustees

Elizabeth Thompson
Chief Executive Officer

SANSUM DIABETES RESEARCH INSTITUTE

100+ YEARS
OF LANDMARK DISCOVERIES

First to Manufacture and Administer Insulin in the U.S.

In 1922, SDRI founder Dr. William Sansum's work jump-started domestic insulin production, set clinical standards for its use and laid the groundwork for today's ever-advancing diabetes therapies—saving millions of lives over the last century

Revolutionizing Pregnancy Diabetes Care Worldwide

Dr. Lois Jovanovic, former CEO and Chief Scientific Officer of SDRI, transformed global standards for treating diabetes during pregnancy, a legacy that still guides today's global protocols for gestational, type 1, and type 2 diabetes

Artificial Pancreas Systems Patented

SDRI secured the first U.S. patent for an automated glucose-control algorithm—the foundation of modern artificial pancreas technology, in collaboration with UC Santa Barbara in 2004

Type 2 Diabetes Prevention in Latino Families

SDRI's first-of-its-kind Ocho Pasos program received national recognition for training community health workers to help Latino families prevent type 2 diabetes

Adaptive Insulin-Dosing Algorithms

For more than 20 years, SDRI has led pivotal artificial pancreas studies—starting with the first implanted glucose sensor and pump, and continuing through the earliest Omnipod 5 closed-loop system, Tandem's Basal-IQ and Control-IQ systems, and Medtronic's 670G and 780G systems—advancing adaptive algorithms that automatically adjust insulin delivery in response to real-time glucose trends

First Closed-Loop Insulin System for Pregnancy

Working with Harvard, Mayo Clinic, and Mount Sinai, SDRI led the first pilot of a closed-loop insulin system built for pregnancies complicated by type 1 diabetes—automating dosing as insulin needs swing rapidly and lowering risks for both mother and baby

SDRI Trials Propel Continuous Glucose Monitoring (CGM) Progress

SDRI's pivotal trials have helped drive major CGM advancements—from eliminating routine finger sticks, enabling Abbott Libre 2 and 3 integration with insulin delivery systems, and contributing to the landmark Dexcom G7 trials that led to FDA approval and the first CGM cleared for use during pregnancy—making glucose monitoring safer, easier, and more accessible

2024 CLINICAL TRIALS

NEXT LEVEL TECHNOLOGY INNOVATION

engaged over

600 participants

including **41** pediatric participants

CONDUCTED 17 CLINICAL RESEARCH STUDIES

for safer and more effective treatments and technologies

Clinical Trials Delivering Real Solutions for People with Diabetes

- **Eight Type 1 Diabetes Studies –** Improved treatments, day-to-day management, and standards of care
- **First Omnipod 5 Automated Insulin Delivery (AID) System Trial in Type 2 Diabetes –** Demonstrated lower HbA1c levels across socioeconomically, racially, and ethnically diverse populations
- **Continuous Ketone Monitoring (CKM) –** Conducted studies on CKM sensors designed to detect ketone fluctuations early, before they escalate to life-threatening diabetic ketoacidosis in patients with type 1 diabetes

Advancing Approaches to Diabetes Management

- **Inhaled + Basal Insulin –** Evaluated inhaled insulin, combined with basal insulin, as a potential treatment for post-meal glucose spikes in people with type 1 diabetes
- **Closed-Loop Systems for Type 2 Diabetes –** Conducted two landmark closed-loop automated insulin delivery studies addressing the unique challenges like insulin resistance and variable insulin needs

Women's Health: Transforming Diabetes Care in Pregnancy

Clinical trials that advanced maternal care:

- **Earlier, More Accurate Diagnosis of Gestational Diabetes Mellitus (GDM):** Evaluated Continuous Glucose Monitor (CGM) technology as a diagnostic tool
- **Better Glycemic Control for GDM –** Proved real-time CGM improves glucose management during pregnancy and postpartum
- **Culturally Tailored Support –** Tested nutrition and lifestyle interventions for pregnant Latina women with type 2 diabetes or GDM

2024 Findings Shared on the Global Stage

- **American Diabetes Association Scientific Sessions, Orlando, FL**
- **DiabetesMine Innovation Days, San Diego, CA**
- **European Association for the Study of Diabetes (EASD) Annual Meeting, Madrid, Spain**
- **Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, New Orleans, LA**

IDEAS TO IMPACT

SDRI Published 14 articles in highly respected medical journals, accelerating the development of new treatments, technologies, and strategies to improve diabetes care. Our top publications include:

1. Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes (Diabetes Technology and Therapeutics)

2. Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical Trial (Diabetes Care)



3. A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery (Diabetes Care)

4. Concordance of Blood Glucose and CGM During a Pilot Trial of Automated Insulin Delivery in Type 1 Diabetes Pregnancies (Journal of Endocrine Society)

5. A review of CONCEPTT study findings including sub analyses in pregnant women using continuous glucose monitoring with type 1 diabetes and their offspring (Endocrine Connections)

REALIZING THE FUTURE OF DIABETES CARE

Pediatric Screen and Treat

Our goal for the Pediatric Screen and Treat program is to raise community awareness about the importance of T1D screening, one of childhood's most common autoimmune diseases, and to reduce the health risks associated with delayed diagnosis of this disease in children.

Why screen for early Type 1 Diabetes?

- Most children with T1D (90%) do not have a family member with T1D
- Symptoms of T1D can be hard to recognize and include increased thirst, frequent urination, unexplained weight loss, and fatigue
- Screening for T1D with a simple blood test for T1D-associated antibodies can identify children who are at high risk of developing T1D and prevent a child from becoming very sick with life-threatening diabetic ketoacidosis (DKA) and needing treatment in a pediatric intensive care unit
- Armed with the information from screening, individuals and families may be able to participate in studies of new interventions that might stop or slow the progress of T1D

Approved Treatment

In 2022, the FDA approved TZIELD (teplizumab), which could delay the onset of clinical type T1D. It is approved for adults and pediatric patients aged 8 years and older with 2 or more T1D-associated autoantibodies and elevated fasting blood glucose. Research shows that people who received TZIELD had an average of 2 more years before the onset of clinical T1D.

World Class Research – Santa Barbara Based

Innovative Research Inspiring Hope

A campaign for Sansum Diabetes Research Institute

Innovative Research, Inspiring Hope is a time-sensitive initiative to modernize SDRI's facilities and accelerate diabetes breakthroughs– creating a space where science defies limits.

Unraveling the Unique Impact of Diabetes on Women's Health

For over 50 years, SDRI researchers have led life-saving initiatives in women's health to ensure better health outcomes for women with, or at risk of, diabetes during pregnancy. We continue to be interested in expanding our research focus to include perimenopause to menopause through the end of life.

As individuals vary in their response to diabetes, understanding sex-specific differences becomes crucial in developing tailored and effective treatment approaches. Women living with diabetes are at a heightened risk following gestational diabetes, a heightened risk of cardiovascular complications, and an association between early menopause and type 2 diabetes.

As researchers continue to delve into this captivating field, it becomes evident that sex-specific considerations are paramount in managing diabetes effectively. Recognizing and addressing the unique challenges faced by women with diabetes can pave the way for targeted interventions, better health outcomes, and an improved quality of life for millions of individuals worldwide.

Our Goals Include:

- Developing data sources and tools to further the understanding of diabetes in pregnant women
- Creating teaching and training modules for OBGYNs and family practice healthcare providers providing care for pregnant women with diabetes based on real-world evidence
- Providing wrap-around care for high-risk women and their babies through SDRI's clinic
- Developing culturally sensitive content and deliver community education for at-risk Hispanic women
- Initiating and implementing clinical clinical research trials for pregnant women that generate meaningful advances

Renovations are underway to complete SDRI's state-of-the-art research facility in 2026 and attract top-tier scientists to build upon SDRI's 100+ year legacy of world-renowned research.

DISCOVERY THAT MAKES A DIFFERENCE

SDRI's Program Highlights

- **LADATalk:** A monthly support group fostering connection and improved diabetes management for those with Latent Autoimmune Diabetes in Adults (LADA).
- **T1D Support:** OneTalk sessions, family outreach events, and research presentations that empower patients with the latest diabetes updates.
- **Returning to School with Diabetes Town Hall:** SDRI co-hosted the 5th annual event in collaboration with the American Diabetes Association and Breakthrough T1D. The event featured diabetes and mental health experts who addressed the emotional and practical challenges of managing diabetes in school.
- **Ocho Pasos:** An eight-week Spanish-language program that offers culturally relevant nutrition education, physical activity, and diabetes self-management. This program is taught by SDRI-trained Community Health Workers (CHWs) and aims to improve T2D within the Latino community, which faces cultural and systemic barriers to care.
- **Semillas de Cambio con Cariño (Seeds of Change with Tenderness):** A culturally tailored diabetes education program aimed at improving blood glucose levels, metabolic health, and pregnancy outcomes for underserved Latina women with prediabetes, gestational diabetes mellitus (GDM), and type 2 diabetes (T2D) during pregnancy.

FINANCIALS AT-A-GLANCE



2024 Gifts Received

	FORM 990
Research Contracts	$2,258,524
Contributions & Grants	$2,056,749
Patient Care	$49,965
Other Revenue	$27,883
TOTAL REVENUE	**$4,393,121**

Charity Navigator ✦ FOUR-STAR ✦

Platinum Transparency 2024 Candid.

In 2024, SDRI was once again recognized by two of the most trusted independent charity evaluators—Candid and Charity Navigator—for excellence in transparency, accountability, and impact. Earning their highest ratings reaffirms our commitment to integrity and efficiency in everything we do.

As we advance groundbreaking work in diabetes research, education, and clinical care, we are deeply grateful for your continued support. Together, we are improving lives and creating a healthier future for millions impacted by diabetes worldwide.

2024 DONORS

Campaign Donors

We are profoundly grateful to the generous donors who have supported Sansum Diabetes Research Institute's campaign, Innovative Research, Inspiring Hope. The following individuals and organizations have made gifts that directly contribute to the next generation of diabetes treatments, helping SDRI maintain its leadership in diabetes research and innovation.

Campaign Leadership Donors:

Ann Jackson Family Foundation

Anonymous

Tim and Louise Casey

Thomas and Nancy S. Crawford

The Gretler Foundation

Hutton Parker Foundation

Norman A. Kurland and Deborah David

La Centra - Sumerlin Foundation

Loon Point Fund

Fred and Joyce Lukas

The Ogle Family

Board Trustee Norman Kurland and volunteer Deborah David joined supporters and advocates at Taste of the Vine for an evening of dining, entertainment, and auctions—all benefiting SDRI's research and programs.

The Paskin Family Foundation

The Radaz Family*

Bob and Ruth Reingold

Betty D. Zaninovich*

** (deceased)*

Campaign Donors:

Anonymous

Joan Doell Arnold

Mr. and Mrs. Albert Bellas

Dr. and Mrs. Daniel Berger

Dr. Kathryn Brewer

Mr. Anthony Castillo

Alex and Laura DePaoli

Ms. Elena Engel and Mr. Andrew Konigsberg

Ms. Deborah Gibson

Mr. and Mrs. Ron Hein

Johnson & Johnson

The Jovanovic Family

Mr. Steven Jung and Dr. Lois Barnes

Dr. Yasue Omori

Robert and Rita Elmen Foundation

Matt and Natalie Rowe

The Sloan Family

Mrs. Sandra Tillisch Svoboda

Ken and Shirley Waxman

Dr. and Mrs. Brad Webb

Yardi Systems

2024 Donors

We extend our gratitude to the individuals and organizations whose generosity supported Sansum Diabetes Research Institute's mission in 2024. The following donors have made it possible for us to advance research, education, and clinical care for those impacted by diabetes.

$100,000 +

Alfred E. Mann Charities, Inc.

Anonymous

Beyond Obesity

Thomas and Nancy S. Crawford

The Gretler Foundation

Hutton Parker Foundation

The Ogle Family

The Paskin Family Foundation

Bob and Ruth Reingold

Robert and Rita Elmen Foundation

William K. Bowes, Jr. Foundation

Taste of the Vine Co-Chair Wendy Thies Sell and her husband, Michael, enjoyed an evening in support of SDRI's mission to advance diabetes research at Taste of the Vine.

$50K - $99.9K

La Centra-Sumerlin Foundation

Santa Barbara Foundation

Turner Charitable Memorial Trust

$25K - $49.9K

Anonymous

The Coeta and Donald Barker Foundation

Redman Family Trust

$10K - $24.9K

Anonymous (x2)

Joan Doell Arnold

Central Coast Capacity Building Collaborative

Mr. and Mrs. Eric Free

The James M. and Margaret V. Stine Foundation

Mr. and Mrs. Howard Kootstra

Ms. Carol MacCorkle

Mark and Dorothy Smith Family Foundation

Max Lynn and Shirley A. Lynn Memorial Foundation

Mechanics Bank

Ontario International Airport

The Ryerson Family Foundation

Silicon Valley Community Foundation

St. Francis Foundation

If you notice an error or omission, please accept our sincere apologies and contact ***khornbuckle@sansum.org*** *so we can make the correction.*

Dr. Daniel Berger, Lindsey Duca, Joan Arnold, Elena Engel, and Steve Jung—SDRI Board Trustees and dedicated supporters—were among the many who made Taste of the Vine a meaningful evening.

$5K - $9.9K

Anonymous
Banc of California
Gerri and Laszlo Bock
Mr. and Mrs. Douglas Boyd
Mr. and Mrs. James Cherry
Ms. Katie DeWitt
Jan and David Edwards
Jenny Edwards and Alex Parraga
The Eibshutz-Raphan Foundation
Ms. Elena Engel and Mr. Andrew Konigsberg
Float Luxury Spa
Frank Schipper Construction Co.
Ms. Yvette Giller
Ms. Susan Hayward
Henry E. and Lola Monroe Foundation
Norman A. Kurland and Deborah David
Loon Point Fund

Board Trustees Daren Dickerson, Flint Ogle, and Matthew Rowe joined guests at Taste of the Vine for an evening of exceptional food, fine wines, and community celebration.

Montecito Bank & Trust
Ellen Lehrer Orlando and Thomas Orlando
Mr. and Mrs. Scott Silver
The Sloan Family
Amy Stewart
Dr. Gerald Svedlow and Ms. Catherine Breen
The Towbes Foundation
Mr. Eric Upin
Dr. and Mrs. Kenneth Waxman
Zegar Family Fund

$1K - $4.9K

The American Gift Fund
Dr. Alan Bachrach
Mr. and Mrs. Henry Baier
Mr. Charles Beattie
The Benevity Community Impact Fund
Dr. and Mrs. Daniel Berger
Beta Bionics
Mr. and Mrs. Christopher Boise-Cossart
The Boyd Foundation
Ms. Sherry Boyer
Mr. William Boyle
Tim and Louise Casey
Mr. Anthony Castillo
Mr. and Mrs. Fredrick Chynoweth
Mr. Gerald DeWitt
Mr. and Mrs. Daren Dickerson
Mr. and Mrs. Stephen Dorsi
Emma Magnus Williams Trust
Ms. Nancy Even and Mr. Joel Ohlgren
Dr. and Mrs. Ken Faulk
Mr. and Mrs. John Foster
Mr. and Mrs. Stephan Frenkel
Mr. and Mrs. Bob Gates
Grating Pacific
Give Lively Foundation Inc.
The Hamman Family
Jim Harris
Mr. and Mrs. Christopher Haskell
Ms. Nancy Heffron
Jeff and Kara Hornbuckle
Mr. and Mrs. Tracy Hornbuckle
Mr. and Mrs. John Jostes
Mosher Foundation
Mr. and Mrs. Anthony Nagy, Jr.
Nissenson Family Fund
Ms. Mara Parker
Poomer Fund
Matt and Natalie Rowe
RxSugar
Mel and Irene Sahyun
Mrs. Nadia Schmiedigen
Ms. Wendy Thies Sell and Mr. Michael Sell
Mr. William Shepherd
Ms. Jodi Snekvik
Mr. John Spence
Mr. and Mrs. Gordon Sprague
Mr. and Mrs. Middleton Squier

Taste of the Vine Co-Chair Tamara Free enjoyed the evening with friends in support of SDRI. Pictured from left to right: Gerri Bock, Amy Stewart, Joy Silver, Tamara Free, and Susan Hayward.

Mr. Steven Jung and Dr. Lois Barnes
Mr. and Mrs. Michael Karmelich
Ms. Susan Keller
Mr. and Mrs. Bill Kimsey
Mr. William Klansek and Ms. Sheri Eckmann
Ms. Lois Kroc
MannKind Corporation
Mr. and Mrs. Bob Marshall
Ms. Mary Maxwell
Mr. Thomas McKee
Dr. and Mrs. Lowell McLellan
Ms. Terra Thomas
Ms. Elizabeth Thompson
Dr. Ashley Thorsell and Mr. Clint Scheuerman
Dr. Angelina Trujillo
Mr. David Tufts and Ms. Cris Dovich
Mr. Richard Weeks
Dr. Mark Wilson
Mr. and Mrs. Allen Wold
Betty D. Zaninovich*
Mr. Eric Zilley
** (deceased)*

For a comprehensive list of gifts please visit:
sansum.org/2024-impact-report

SANSUM DIABETES
RESEARCH INSTITUTE

Dedicated to improving the lives of people impacted by diabetes through research, education, and clinical care.

Sansum Diabetes Research Institute is a 501(c)(3) non-profit organization. Tax ID #95-1684086.

5425 Hollister Ave, Suite 230, Santa Barbara, CA 93111

sansum.org | (805) 682-7640 | info@sansum.org